Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,126.06
(
1.20%
)
US TECH 100
25,958.80
(
1.33%
)
Dow Jones
49,447.43
(
1.88%
)
Brent Oil
91.81
(
-0.92%
)
Bitcoin
74,797.99
(
1.27%
)
News Focus
News Focus
Post# of 257426
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122876
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 238083

Wednesday, 05/19/2021 6:35:32 PM

Wednesday, May 19, 2021 6:35:32 PM

Post# of 257426
From BMY’s PR:

[Relatlimab + Opdivo] is the first regimen to demonstrate a statistical benefit over anti-PD-1 monotherapy in metastatic melanoma.

This is true, but there’s a twist: For historical reasons, Opdivo + Yervoy was never tested against Opdivo monotherapy in 1L-melanoma. Rather, it was tested against Yervoy monotherapy.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today